KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development: 2009-2025

Historic Research & Development for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $256.0 million.

  • Teva Pharmaceutical Industries' Research & Development rose 6.67% to $256.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $994.0 million, marking a year-over-year increase of 1.64%. This contributed to the annual value of $998.0 million for FY2024, which is 4.72% up from last year.
  • Teva Pharmaceutical Industries' Research & Development amounted to $256.0 million in Q3 2025, which was up 4.92% from $244.0 million recorded in Q2 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Research & Development ranged from a high of $269.0 million in Q2 2024 and a low of $175.0 million during Q3 2022.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Research & Development value was $244.0 million (recorded in 2025), while the average stood at $245.4 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Research & Development fell by 21.17% in 2022 and then spiked by 44.57% in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Research & Development (Quarterly) stood at $244.0 million in 2021, then fell by 13.93% to $210.0 million in 2022, then increased by 8.10% to $227.0 million in 2023, then rose by 8.81% to $247.0 million in 2024, then grew by 6.67% to $256.0 million in 2025.
  • Its Research & Development was $256.0 million in Q3 2025, compared to $244.0 million in Q2 2025 and $247.0 million in Q1 2025.